42 results about "Cell response" patented technology

A polymeric nanoparticle is disclosed which comprises:(i) at least one disease-associated antigen which is capable of producing a T-cell response, wherein the disease-associated antigen is encapsulated in the nanoparticle;(ii) at least one adjuvant; and(iii) a dendritic cell targeting moiety which is attached to the outer surface of the nanoparticle.Use of the nanoparticle for treating diseases associated with abnormal cell growth or an infection is also disclosed.

Disclosed herein are branched chain amino acid transaminase 1 (BCAT1) inhibitors and uses thereof. More specifically, disclosed are BCAT1 inhibitors that limit amino acid metabolism essential for CD4+ T-cell responses and their use in preventing, improving, or treating inflammatory disease or autoimmune disease. By identifying that BCAT1 acts as a major regulator in the inflammatory response of CD4+ T-cells, it is possible to regulate the inflammatory response by CD4+ T cells secreting interleukin-17 (IL-17), which is a major immune cell of autoimmune diseases, by utilizing a BCAT1 inhibitor.

The invention provides a novel vaccine adjuvant and application of the novel vaccine adjuvant in preparation of the vaccine adjuvant. The BCG-PSN and vaccine induced RBD specific IgG antibody and neutralizing antibody level are equivalent to those of an aluminum adjuvant, the BCG-PSN and vaccine induce Th1 biased T cell reaction, the induced T cell response level is obviously higher than that of the aluminum adjuvant, and K18-hACE2 mice are protected from being affected by Delta variant induced lung lesions. As a vaccine adjuvant, BCG-PSN has wide compatibility and safety, and has no toxic or side effect.

The invention discloses a laminar flow micro-fluidic chip and method for detecting spatial heterogeneous drug distribution influence, the chip comprises a fluid layer and a control layer, the fluid layer comprises a first main inlet and a second main inlet, the fluid layer further comprises a plurality of independent cell culture chambers of an array, the control layer comprises a control valve inlet and a pneumatic valve array, and the control valve inlet is communicated with the pneumatic valve array. The independent cell culture chamber is composed of a concave cavity, the independent cell culture chamber is provided with two semicircular enclosures, a first channel inlet and a second channel inlet are formed in the independent cell culture chamber, and peristaltic pump subunits are arranged on the first channel inlet and the second channel inlet. Laminar flow control is achieved by integrating the pneumatic valve and the peristaltic pump, and chemical gradient generation and cell response monitoring of micron-sized spatial resolution are achieved through automatic control.

Systems and methods for identifying cellular responses to candidate drugs, including treatment cycling, are described. These systems and methods utilize rapid response readout in combination with gentle removal and / or exchange of the analyte fluid. The systems and methods can be used, for example, in T-cell epitope mapping, T-cell diagnostics, and other cell-based high-throughput screening methods.

A method for preparing cells for therapeutic use is provided, comprising culturing a population of progenitor cells under cell culture conditions that promote progenitor cell differentiation, including the presence of G-CSF, GM-CSF, IL-3, and TNF, to generate a population of granulocyte-producing cells. The generated granulocyte-producing cells may be useful in therapeutic methods, including the treatment of cancer and infections, and may also be useful in modulating inflammatory cell responses.

The invention relates to a cell culture reactor in a full temperature control mode, and relates to the technical field of cell culture reaction equipment. The cell culture reactor in the full temperature control mode comprises a shell, a heating cavity is formed in the shell, a bottom plate and a bottom heater are arranged in the heating cavity, the bottom plate is used for placing a cell reaction bag, the bottom heater is used for heating the bottom plate, a cavity heating mechanism is further arranged in the shell, and the cavity heating mechanism is used for heating the cell reaction bag. And the cavity heating mechanism comprises a heating fan, and the heating fan is used for heating gas in the heating cavity. The device has the effect of ensuring the heating uniformity of the cell reaction bag.

Cell analysis systems and instruments provide end users with time history graphics and imaging data of individual cell responses as caused by perturbations in the cell microenvironment and monitored by ChemFET sensors. The imaging data of the cellular response may be presented as an electron microscope image that is either an image taken from a sensor covering a cell footprint at a defined sampling interval of the cellular response or an image of the cellular response for a sensor detecting cellular effluents. Electron microscope imaging may be compared to optical imaging to provide information about additional dimensions of cellular analysis. For example, optical imaging using a known set of markers to compare immunocytochemical studies provides functional and phenotypic characteristics of data obtained for each cell analyzed using a ChemFET-based cellular analysis system.

The present invention provides compounds and compositions for inhibiting complement-mediated damage to cells, tissues, or organs. [Solution] The present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. Furthermore, it provides methods for using cell-reactive compstatin analogs, for example, to inhibit complement-mediated damage to cells, tissues, or organs, for example, to treat complement-mediated disorders. Furthermore, it provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. Furthermore, it provides methods for using long-acting compstatin analogs, for example, to inhibit complement-mediated damage to cells, tissues, or organs, for example, to treat complement-mediated disorders. Furthermore, it provides targeted compstatin analogs and compositions comprising targeted compstatin analogs.

Reprogramming adult or somatic cells into induced pluripotent stem cells (iPSCs) is widely recognized as an inefficient process, with success rates typically below 1%, and is characterized by significant heterogeneity. Numerous strategies have been explored to enhance reprogramming efficiency, including chemical, biochemical, and biophysical manipulations. However, achieving high-efficiency iPSC production and generating cell lines with consistent molecular properties that enable reliable dow nstream differentiation into therapeutically or diagnostically relevant cell ty pes remain poorly understood. The compositions and methods described herein address these challenges by significantly improving the efficiency of iPSC reprogramming. Moreover, the resulting iPSCs exhibit molecular characteristics that enhance cellular responses and differentiation capabilities, allowing for optimization in specific therapeutic and diagnostic applications.

The invention relates to a human body self-adaptive micro-current stimulation method and system.The electrode points of the human body self-adaptive micro-current stimulation system are arranged in an array mode on a two-dimensional structure, the corresponding electrode points are controlled to output multi-frequency micro-current detection signals to all detected areas according to a preset point scanning mode, and cell response data are collected; performing feature extraction on the cell response data, and constructing a response state model of the detected area; acquiring a macroscopic model library and a microscopic model library, performing primary comparison on the response state model and the macroscopic model library, and determining personalized stimulation parameters according to a primary comparison result; performing secondary comparison on the response state model and the microscopic model library, and determining an optimal stimulation electrode combination according to a secondary comparison result; and generating an optimal treatment scheme according to the optimal stimulation electrode combination and the personalized stimulation parameters, and performing electrical stimulation on a target stimulation part of the treatment object through an electrode stimulation module.

This invention provides a tumor peptide vaccine for treating breast cancer and a method for preparing the same, wherein the tumor peptide vaccine comprises: a peptide mixture containing 8 CD8+ molecules. + T cell epitopes peptide fragments and 3 CD4+ + polypeptide fragments of T cell epitopes; the eight CD8... + The amino acid sequences of the polypeptide fragments of T cell epitopes are shown in SEQ ID NO: 1-8, and the three CD4 lines... + The amino acid sequences of the polypeptide fragments of T cell epitopes are shown in SEQ ID NO: 9-11; all of the polypeptide fragments are synthesized from mutant polypeptide sequences of the tumor-associated gene SWAP70; the present invention has the beneficial effect of effectively promoting the generation of T cell responses in the body and is applicable to the field of tumor immunology.

The application discloses a kind of based on knowledge graph's cancer cell line drug response prediction large language model construction method.The method fuses the structured information of biological knowledge graph and the semantic reasoning ability of large language model, realizes the multi-level modeling and explainable prediction of drug-cell reaction mechanism.The method comprises the following steps: first, integrate multi-source data to construct multi-modal dataset;Second, establish the drug response knowledge graph containing drug, gene and other entities;Then, fine-tune the model using LoRA technology and inject graph embedding, realize cross-modal alignment;Further, dynamic knowledge retrieval and enhancement are carried out using RAG technology;Finally, output drug sensitivity prediction and natural language explanation.The application significantly improves the prediction accuracy and explainability, and can reveal the key gene pathway, providing an efficient intelligent tool for precision cancer treatment.

The present disclosure provides antibodies specific for glypican-3 (GPC3). Nucleic acids that encode one or both of the variable chain polypeptides of an antibody of the present disclosure are also provided, as are cells that include such nucleic acids. Also provided are compositions that include the antibodies of the present disclosure, including in some instances, pharmaceutical compositions. Methods of making and using the antibodies of the present disclosure are also provided. In certain aspects, provided are methods that include administering to an individual having a cell proliferative disorder a therapeutically effective amount of an antibody of the present disclosure, where the antibody is administered to the individual to enhance an immune response, e.g., a T cell response, to abnormally proliferating cells of the cell proliferative disorder. The antibodies are useful in various diagnostic, and monitoring applications, which are also provided.

The present disclosure provides compositions that provide positive allosteric modulator compounds of the beta-adrenergic receptor in combination with a beta-arrestin-biased beta-blocker, such as carvedilol, for the treatment of cardiovascular diseases and disorders, such as hypertension and heart failure, wherein the effectiveness of the beta-blocker is enhanced by positively augmenting carvedilol-stimulated cellular responses.

The invention discloses a single-cell drug response prediction method based on two-channel comparative learning, and relates to the field of artificial intelligence assisted drug research and development. The invention aims to solve the problem that the existing single-cell drug reaction prediction precision is low. The method comprises the following steps: acquiring an original single cell transcriptome counting matrix corresponding to a to-be-detected single cell, extracting a to-be-detected gene set with an expression counting value greater than 0 from the original single cell transcriptome counting matrix, acquiring a gene identity embedding vector and an expression intensity embedding vector, and acquiring a cellular-level semantic feature vector by utilizing the expression intensity embedding vector; obtaining a structural feature representation vector of a single cell layer by using the gene identity embedding vector; and acquiring a drug response result and a corresponding probability by using the cellular-level semantic feature vector and the structural feature representation vector of the single cell level. The method is used for obtaining the single cell response reaction under the given drug condition.

The utility model discloses a bypass monitoring and cleaning device for cell culture and a cell reaction system, and belongs to the technical field of cell culture devices.The bypass monitoring and cleaning device comprises an on-line monitoring assembly, a connecting pipeline and a cleaning assembly, the on-line monitoring assembly is communicated with the cleaning assembly through the connecting pipeline, and the cleaning assembly is communicated with the on-line monitoring assembly through the connecting pipeline. The online monitoring assembly comprises a transparent flow cell and a bypass electrode, the flow cell is connected with a liquid inlet pipeline and a liquid outlet pipeline, the bypass electrode comprises an electrode tip, and the electrode tip is arranged in the flow cell. According to the bypass monitoring and cleaning device for cell culture and the cell reaction system, whether pollution exists on the bypass electrode or not can be visually checked, and pollution of the bypass electrode can be cleaned.

To provide a system and a method capable of providing a tumor model suitable for accurately predicting the success of therapy.SOLUTION: Systems, compositions, and methods are provided that utilize a three dimensional tumor model that incorporates a tissue barrier (such as a stromal barrier) around tumor cells in culture, allowing for the recapitulation of invivo immune cell responses to tumor cells. Such tumor models are used to accurately evaluate appropriate treatment modes and protocols that would be effective against the individual's tumor. Such tumor models can be used to selectively expand immune cells that respond to the tumor cells utilized in the model. The population of immune cells so expanded can then be utilized therapeutically.SELECTED DRAWING: Figure 4

In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ.

Systems and methods for identifying cellular responses to candidate agents, including a processing cycle, are described. The systems and methods utilize fast reaction readout values in conjunction with mild removal and / or exchange of analyte fluids. For example, the systems and methods may be used in T cell epitope mapping, T cell diagnosis, and other cell-based high throughput screening methods.

The application belongs to the field of biological medicine, and particularly relates to application of mouse B16-MO4 melanoma neoantigen polypeptide and PolyI:C composition in treatment of melanoma, and an amino acid sequence of the neoantigen polypeptide is shown as SEQ ID No. 3, 4, 5, 15, 18. Five tumor neoantigen polypeptides with true immunogenicity are screened, and the tumor neoantigen is prepared into a vaccine preparation by compounding with PolyI:C. After mice are treated by the B16-MO4 tumor vaccine preparation, the growth of the tumor can be effectively inhibited, the survival period of the mice is prolonged, and the neoantigen vaccine preparation produces a very effective T cell response in the tumor-bearing mice.

The present invention provides methods for using waste effluent biofluids in cell culture assays as all or part of the cell culture microenvironment. Methods of the invention contemplate that biofluids typically regarded as waste may be used in cell-based assays to achieve a cell culture microenvironment that provides a novel understanding of cellular response.

Disclosed is a computer-implemented method for identifying, for a subject, at least one antigen which is expected to induce a T-cell response to attack unhealthy cells in the subject. The invention further relates to using said antigens for designing personalized vaccines and to the use of such personalized vaccine and personalized vaccine compositions in kits and methods for the treatment of disease.

Methods for expanding tumor infiltrating lymphocyte (TIL) populations and methods of using the expanded TIL populations to treat cancer are disclosed.

Provided herein are recombinant polynucleotides including a first nucleic acid sequence encoding an antigen, and a second nucleic acid sequence encoding an enzyme of an amino acid catabolic pathway. The provided recombinant polynucleotides are particularly useful for inducing long-lived immune responses having improved memory characteristics. Also provided are pharmaceutical compositions, viral particles, and host cells including the disclosed recombinant polynucleotides, and methods for using the disclosed materials.

The invention discloses preparation of a PVDF / Sr-POM composite fiber membrane and application of the PVDF / Sr-POM composite fiber membrane in dentin regeneration, and belongs to the technical field of functional materials, and the composite fiber membrane is prepared from PVDF / Sr-POM through electrochemical spinning. PVDF has piezoelectricity, and Sr-POM has high flexibility and a high length-diameter ratio; under physiological conditions, mechanical stimulation such as chewing can trigger piezoelectricity to induce the PVDF / Sr-POM composite fiber membrane to realize continuous release of therapeutic Sr < 2 + > so as to stimulate dentin differentiation. The piezoelectric function of PVDF is combined with the biological activity of Sr-POM, so that the synergistic effect is realized, and a dynamic microenvironment with the synergistic effect of physical and chemical signals is created. Under the action of mechanical load, the generated micro voltage and the continuously released Sr < 2 + > coordinate cell reaction together, and a feasible way is provided for realizing efficient and functional dentin regeneration.

The present invention provides a modified mRNA vaccine for dengue virus. Specifically, the present invention provides an mRNA vaccine composition for dengue virus, comprising: (a) mRNA for expressing an immunogen of dengue virus, the immunogen of dengue virus being selected from the group consisting of E80 protein (i.e. the extra-membrane portion of envelope protein E), prME protein, NS1, or a combination thereof; and (b) a pharmaceutically acceptable carrier. Experiments show that the mRNA vaccine of the present invention can induce a super-high level of neutralizing antibodies, which is 10-50 times higher than the antibody level induced by other vaccines in mice, and can induce a strong T cell response against dengue virus, thereby providing complete protection for the immunized animals.

Among the strategies allowing cancer cells to escape the immune system, the presence of Transforming growth factor beta (TGF-β) in the tumor micro-environment (TME) is one of the most potent immunosuppressive mechanisms for many types of tumors. Thus, depleting TGF-β is regarded as a promising potent therapeutic approach to fight cancers, regardless of the type of tumor. However, the major impediment for achieving this objective is that TGF-β belongs to the few cytokines that must be activated once secreted. Moreover, a systemic targeting of TGF-β is associated with profound side effects due to TGF-β ability to sustain the homeostasis of numerous tissues. Hence, selectively targeting of TGF-β activation within the TME appears as a rational approach to boost the anti-tumor response and avoid side effects. The integrin αvβ8 expressed on Tregs specifically promotes TGF-β activation and impairs the anti-CD8 T cell response within the TME of different cancers in both mice and humans. The inventors generated anti-β8 chain of αvβ8 integrin (Itgβ8) neutralizing monoclonal antibodies which specifically bind to Tregs and selectively neutralize the ability of Tregs to activate the TGF-β. Thus, the present invention relates to isolated anti-Itgβ8 neutralizing antibodies which specifically binds to β8 chain of αvβ8 integrin (Itgβ8) expressed on Tregs, and their uses for treating cancer.

The application discloses a LAG-3 binding molecule, which comprises a LAG-3 antibody, or an antigen binding fragment of the LAG-3 antibody, or a fusion protein containing the LAG-3 antibody, or a fusion protein containing the antigen binding fragment, or an antibody drug conjugate containing the LAG-3 antibody, or an antibody drug conjugate containing the antigen binding fragment, or a bispecific antibody containing the LAG-3 antibody or a bispecific antibody containing the antigen binding fragment. The LAG-3 binding molecule provided by the application can bind to human and monkey LAG-3, has high affinity to human LAG-3, effectively enhances T cell response, can be used for regulating T cell and antibody-mediated immune response, and has wide therapeutic uses as an immunomodulator, such as cancer, autoimmune diseases, inflammatory diseases, and infectious diseases.

This invention provides a gas control device for experiments involving hypoxia / reoxygenation of cardiomyocytes. [Solution] The system comprises three parallel intake branch pipes 4 integrating a precision needle-type throttling structure, a multi-stage mixing chamber 6 connected thereto, a gradient switching mechanism, and a pressure balancing device. The gradient switching mechanism includes a fixed plate 9 and a movable plate, with multiple throttling holes of different diameters in the fixed plate and gas passage holes in the movable plate, allowing the airflow cross-sectional area to be switched in steps by rotating the movable plate. This solves the problem of pressure fluctuations during gas environment switching interfering with cellular responses, achieves highly accurate and smooth switching between hypoxia and reoxygenation, eliminates instantaneous pressure pulses, provides an accurate and uniform mixed gas for the hypoxia / reoxygenation (H / R) model, and is applicable to molecular mechanism studies of myocardial ischemia-reperfusion injury (MIRI).